Summary:
The objective of this study is to evaluate the efficacy, safety and tolerability of two fixed dose levels of vilazodone relative to placebo in patients with major depressive disorder (MDD).
Qualified Participants Must:
• Suffer from Major Depression at the time fo study participation
Qualified Participants May Receive:
$50 compensation for all visits they attend except the initial screening visit. The initial screen visit is unpaid.